These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23894903)

  • 1. Adverse events following transarterial chemoembolization for hepatocellular carcinoma and factors predicting such events.
    Tasneem AA; Abbas Z; Luck NH; Hassan SM; Faiq SM
    J Pak Med Assoc; 2013 Feb; 63(2):239-44. PubMed ID: 23894903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
    Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
    Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome.
    Miyayama S; Matsui O
    J Vasc Interv Radiol; 2016 Sep; 27(9):1269-1278. PubMed ID: 27345337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma.
    Nagai H; Matsui T; Kanayama M; Wakui N; Momiyama K; Watanabe M; Igarashi Y; Sumino Y
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):139-45. PubMed ID: 20857114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for the development of pulmonary oil embolism after transcatheter arterial chemoembolization of hepatic tumors.
    Wu GC; Chan ED; Chou YC; Yu CY; Hsieh TY; Hsieh CB; Chian CF; Ke FC; Dai YL; Su WL
    Anticancer Drugs; 2014 Sep; 25(8):976-81. PubMed ID: 24736105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma.
    Heinzow HS; Meister T; Nass D; Köhler M; Spieker T; Wolters H; Domschke W; Domagk D
    Scand J Gastroenterol; 2011 Feb; 46(2):201-10. PubMed ID: 20969491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.
    Boulin M; Ciboulet A; Guiu B; Maillard E; Bonnetain F; Minello A; Gagnaire A; Lepage C; Krause D; Hillon P; Bedenne L; Cercueil JP; Chauffert B; Jouve JL
    Dig Liver Dis; 2011 Nov; 43(11):905-11. PubMed ID: 21802381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
    Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma.
    Chan SL
    Aliment Pharmacol Ther; 2012 Jul; 36(1):74-5; discussion 75. PubMed ID: 22650492
    [No Abstract]   [Full Text] [Related]  

  • 14. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
    Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
    J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare complication after transarterial chemoembolization for hepatocellular carcinoma.
    Huang YS; Chang CC; Chang YC
    QJM; 2014 Jun; 107(6):487-8. PubMed ID: 24170892
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefits and problems of transarterial therapy in patients with hepatocellular carcinoma and chronic kidney disease.
    Watanabe M; Shibuya A; Minamino T; Murano J; Matsunaga K; Fujii K; Ogasawara G; Irie T; Woodhams R; Koizumi W
    J Vasc Interv Radiol; 2014 Dec; 25(12):1947-55; quiz 1955. PubMed ID: 25306225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma.
    Shin JU; Kim KM; Shin SW; Min SY; Park SU; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik SW; Yoo BC; Koh KC
    Dig Liver Dis; 2014 Sep; 46(9):813-7. PubMed ID: 24881853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors.
    Olivo M; Valenza F; Buccellato A; Scala L; Virdone R; Sciarrino E; Di Piazza S; Marrone C; Orlando A; Fusco G; Madonia S; Cottone M
    Dig Liver Dis; 2010 Jul; 42(7):515-9. PubMed ID: 19914153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.